OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
DENVER, Feb. 28, 2017 -- The world’s leading high-quality cannabidiol (CBD) hemp oil brand, Elixinol, announces the availability of its product line in Brazil, making organic CBD available to over 205 million people in Latin America’s most populous country.
“For sufferers of conditions such as epilepsy and multiple sclerosis, Brazil’s recognition of CBD’s therapeutic benefits is an important step towards functional, fulfilling lives and Elixinol is proud to be able to be part of the therapy for treating these very serious conditions,” said Paul Benhaim, CEO of Elixinol.
Although its relationship with cannabis remains complicated, Brazil joins countries like Japan, whose perceptions are shifting as they once again recognize the benefits of hemp.
Doctors in Brazil may prescribe CBD, including Elixinol, for treatment of intractable seizures. In 2014 Federal Medical Council of Brazil)(CFM) officially authorized the compassionate use of CBD for the treatment of intractable epilepsy in children and adolescents.
It is estimated that over 2 million Brazilians suffer from epileptic seizures and over 675,000 suffer from intractable seizures.
In 2015, ANVISA (National Agency of Sanitary Surveillance) defined the procedures for the importation of CBD products into Brazil by individuals, hospitals and health insurance companies, as published in the Resolução da Diretoria Colegiada (RDC) 17/2015.
In 2016, Elixinol hemp oil was included in ANVISA’s list of most frequently imported products and will have a simpler authorization process, as stated in the health agency’s RDC 128/2016.
“It’s an honor to be a working with the medical community, the people and the government of Brazil to bring high-quality, organic hemp relief to the sufferers whose doctors see CBD as a treatment option,” said Dr. Philip Blair, MD, Elixinol Medical Advisor.
About Elixinol:
Colorado-based Elixinol, founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and manufacturing high-quality hemp, Elixinol also conducts rigorous laboratory testing and quality control. A global leader in hemp distribution, Elixinol provides CBD products globally in the United States, Japan, Brazil, Puerto Rico and the UK. More information available at Elixinol.com.
Media Contact: Chris Husong Elixinol 408-420-8890 (m) [email protected]
